Weidmann, Eckhart and Hess, Georg and Chow, Kai U. and Krause, Stefan W. and Subklewe, Marion and Kruse, Judith and Weisel, Katja C. and Soekler, Martin and Kim, Soo-Zin and Napieralski, Simone and Rech, Juergen and Dreyling, Martin and Jaeger, Elke and Mitrou, Paris S. (2010) A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas. LEUKEMIA & LYMPHOMA, 51 (3). pp. 447-455. ISSN 1042-8194, 1029-2403
Full text not available from this repository. (Request a copy)Abstract
The clinical course of peripheral T-cell lymphoma (PTCL) is usually aggressive and the prognosis unfavorable. Therefore, there is a need for improvement of treatment options. Patients with newly diagnosed (n = 27) or refractory/relapsed (n = 11) PTCL received a combination of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin. The overall response rate (ORR) was 61%, with a complete response rate of 39%. In newly diagnosed patients the ORR was 63%, the median overall survival 25.9 months, and progression-free survival 11.8 months. In relapsed/refractory patients the median OS was 6.1 months. The most frequent grade 3/4 toxicities were leukopenia (95% of patients) and thrombocytopenia (58%). Cytomegalovirus (CMV) reactivation occurred in 12 patients, but only two had CMV disease. Treatment-related deaths occurred in six newly diagnosed patients and one with relapsed/refractory disease. In conclusion, Campath-FCD is active in PTCL but is associated with significant toxicity and is, therefore, not recommended for use or further study. Further studies are warranted to investigate other approaches to combining alemtuzumab with chemotherapy for the treatment of PTCL.</.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | CHRONIC LYMPHOCYTIC-LEUKEMIA; MYCOSIS FUNGOIDES/SEZARY-SYNDROME; ANTI-CD52 MONOCLONAL-ANTIBODY; NON-HODGKINS-LYMPHOMAS; CARDIAC TOXICITY; CHEMOTHERAPY; COMBINATION; THERAPY; MANAGEMENT; TRIAL; Alemtuzumab; fludarabine; peripheral T-cell lymphoma (PTCL) |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 05 Aug 2020 10:10 |
| Last Modified: | 05 Aug 2020 10:10 |
| URI: | https://pred.uni-regensburg.de/id/eprint/25100 |
Actions (login required)
 |
View Item |
